drugset / Trial / NCT00271713
Impact of Oral Ibandronate 150 mg Monthly on Structural Properties of Bone in Postmenopausal Osteoporosis (SPIMOS-3D)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Efficacy: To investigate changes of structural bone properties in vivo using 3DpQCT ("Xtreme" CT, Scanco) in monthly oral ibandronate therapy for women with postmenopausal osteoporosis. Major structural bone parameters which determine bone strength and predict fracture risk earlier and more precisely are measurable in vivo by 3DpQCT. Safety: To assess the tolerability and safety of ibandronate therapy
Timeline
- Start
- 2006-03
- Primary completion
- 2007-09
- Completion
- 2007-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Ibandronate | Other / unclassified | 150 mg | Oral |
| Comparator | Calcium carbonate | Other / unclassified | 500 mg | — |
| Comparator | Vitamin D | Other / unclassified | 800 iu | — |